SCHEMBL111117

SCHEMBL111117

Cc1cc(C)n(CC(=O)N2CCN(c3ccccc3NC(=O)c3cccnc3)CC2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.58
ALDH1A1 P00352 4/20 0.58
CXCR3 P49682 2/20 0.58
KCNH2 Q12809 1/20 0.58
USP2 O75604 1/20 0.58
ABL1 P00519 1/20 0.58
RIN1 Q13671 1/20 0.58
HSD17B10 Q99714 1/20 0.55
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
REV1 Q9UBZ9 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
HPGD P15428 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111124 0.91 CXCR3 (0.67) TSHRALDH1A1CXCR3KCNH2USP2
SCHEMBL112537 0.90 CXCR3 (0.61) TSHRALDH1A1CXCR3KCNH2USP2
SCHEMBL166583 0.88 CXCR3 (0.56) TSHRALDH1A1CXCR3KCNH2USP2
SCHEMBL164171 0.86 KDM4E (0.58) TSHRALDH1A1CXCR3KCNH2USP2
SCHEMBL111638 0.86 CYP1A2 (0.65) TSHRALDH1A1CXCR3KCNH2USP2
SCHEMBL111879 0.85 CXCR3 (0.60) TSHRALDH1A1CXCR3KCNH2USP2
SCHEMBL164307 0.84 CXCR3 (0.61) TSHRALDH1A1CXCR3KCNH2HSD17B10
SCHEMBL159697 0.84 CXCR3 (0.49) TSHRALDH1A1CXCR3KCNH2USP2
SCHEMBL112176 0.83 TSHR (0.58) TSHRALDH1A1CXCR3KCNH2HSD17B10
SCHEMBL112242 0.82 CXCR3 (0.54) TSHRALDH1A1CXCR3KCNH2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
EP-2424858-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 TSHR 543/4885ALDH1A1 1720/4885CXCR3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.